Bicycle Stock Analysis

The current indifference towards the small price fluctuations of Bicycle Therapeutics Plc could raise concerns from investors as the firm it trading at a share price of 0.0 on very low momentum in volume. The company directors and management did not add any value to Bicycle Therapeutics investors in July. However, most investors can still diversify their portfolios with Bicycle Therapeutics Plc to hedge their inherited risk against high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently very low. The very small Stock volatility is a good signal to investors with longer-term investment horizons.
Check out Trending Equities.

Search Stock Analysis 

 
Refresh
The Bicycle Therapeutics stock analysis report makes it easy to digest most publicly released information about Bicycle Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Bicycle Stock analysis module also helps to analyze the Bicycle Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Bicycle Stock Analysis Notes

About 61.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 4.99. Bicycle Therapeutics Plc had not issued any dividends in recent years. Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom. Bicycle Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 87 people. For more info on Bicycle Therapeutics Plc please contact the company at 44 1223 261 503 or go to http://www.bicycletherapeutics.com.

Bicycle Therapeutics Plc Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Bicycle Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Bicycle Therapeutics Plc or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Bicycle Therapeutics is not yet fully synchronised with the market data
Bicycle Therapeutics has some characteristics of a very speculative penny stock
Bicycle Therapeutics is unlikely to experience financial distress in the next 2 years
The company reported the previous year's revenue of 11.07 M. Net Loss for the year was (55.88 M) with loss before overhead, payroll, taxes, and interest of (22.76 M).
Bicycle Therapeutics Plc currently holds about 195.9 M in cash with (52.66 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.14.
Bicycle Therapeutics has a poor financial position based on the latest SEC disclosures
Roughly 61.0% of the company shares are held by institutions such as insurance companies

Bicycle Therapeutics Plc Upcoming and Recent Events

Earnings reports are used by Bicycle Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Bicycle Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report4th of August 2021
Next Earnings Report4th of November 2021
Next Fiscal Quarter End30th of June 2021
Next Fiscal Year End10th of March 2022
Last Quarter Report31st of March 2021
Last Earning Announcement30th of June 2020

Bicycle Therapeutics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Bicycle Therapeutics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Bicycle Therapeutics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Bicycle Therapeutics Plc specific information freely available to individual and institutional investors to make a timely investment decision.
28th of July 2021
Unclassified Corporate Event
View
13th of July 2021
Financial Statements and Exhibits. Unregistered Sales of Equity Securities. Entry into a Material Definitive Agreement
View
28th of June 2021
Submission of Matters to a Vote of Security Holders
View
24th of May 2021
Financial Statements and Exhibits. Other Events
View
6th of May 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
16th of April 2021
Unclassified Corporate Event
View
9th of April 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
2nd of April 2021
Financial Statements and Exhibits. Other Events
View

Bicycle Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 764.68 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Bicycle Therapeutics's market, we take the total number of its shares issued and multiply it by Bicycle Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Bicycle Profitablity

Bicycle Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Bicycle Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Bicycle Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Bicycle Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Bicycle Therapeutics' profitability requires more research than a typical breakdown of Bicycle Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2021
Return on Average Assets(0.35) (0.38) 
Return on Average Equity(0.57) (0.62) 
Return on Invested Capital(4.53) (4.89) 
Return on Sales(4.93) (5.32) 

Management Efficiency

The entity has return on total asset (ROA) of (19.94) % which means that it has lost $19.94 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (49.91) %, meaning that it created substantial loss on money invested by shareholders. Bicycle Therapeutics management efficiency ratios could be used to measure how well bicycle therapeutics plc manages its routine affairs as well as how well it operates its assets and liabilities. As of August 1, 2021, Return on Average Assets is expected to decline to -0.38. In addition to that, Return on Average Equity is expected to decline to -0.62. Bicycle Therapeutics Assets Non Current are projected to increase significantly based on the last few years of reporting. The past year's Assets Non Current were at 5.43 Million. The current year Asset Turnover is expected to grow to 0.08, whereas Total Assets are forecasted to decline to about 146.6 M.
Last ReportedProjected for 2021
Book Value per Share 4.99  5.38 
Enterprise Value over EBIT(5.00) (5.39) 
Enterprise Value over EBITDA(4.95) (5.34) 
Price to Book Value 4.01  3.79 
Tangible Assets Book Value per Share 8.42  8.64 
Enterprise Value247.7 M223.5 M
Tangible Asset Value161.2 M146.6 M

Bicycle Therapeutics Plc Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bicycle Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bicycle Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bicycle Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Lee Kevin few days ago via Macroaxis 
Exercise or conversion by Lee Kevin of 100 shares of Bicycle Therapeutics subject to Rule 16b-3
Bingham Kate over a week ago via Macroaxis 
Sale by Bingham Kate of 917 shares of Bicycle Therapeutics
Bingham Kate over two weeks ago via Macroaxis 
Sale by Bingham Kate of 917 shares of Bicycle Therapeutics
Crockett Nigel over two weeks ago via Macroaxis 
Exercise or conversion by Crockett Nigel of 13019 shares of Bicycle Therapeutics subject to Rule 16b-3
Crockett Nigel over three weeks ago via Macroaxis 
Exercise or conversion by Crockett Nigel of 271 shares of Bicycle Therapeutics subject to Rule 16b-3
Lee Kevin over two months ago via Macroaxis 
Exercise or conversion by Lee Kevin of 5604 shares of Bicycle Therapeutics subject to Rule 16b-3
Lee Kevin over two months ago via Macroaxis 
Exercise or conversion by Lee Kevin of 897 shares of Bicycle Therapeutics subject to Rule 16b-3
Lee Kevin over three months ago via Macroaxis 
Exercise or conversion by Lee Kevin of 30406 shares of Bicycle Therapeutics subject to Rule 16b-3
Lee Kevin over three months ago via Macroaxis 
Exercise or conversion by Lee Kevin of 6636 shares of Bicycle Therapeutics subject to Rule 16b-3
Legault Pierre over three months ago via Macroaxis 
Exercise or conversion by Legault Pierre of 24838 shares of Bicycle Therapeutics subject to Rule 16b-3
Legault Pierre over three months ago via Macroaxis 
Exercise or conversion by Legault Pierre of 162 shares of Bicycle Therapeutics subject to Rule 16b-3
Keen Nicholas over three months ago via Macroaxis 
Sale by Keen Nicholas of 10000 shares of Bicycle Therapeutics

Bicycle Therapeutics Technical and Predictive Indicators

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Bicycle Therapeutics to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Equity Valuation Now

   

Equity Valuation

Check real value of public entities based on technical and fundamental data
All  Next Launch Module
Check out Trending Equities. Note that the Bicycle Therapeutics Plc information on this page should be used as a complementary analysis to other Bicycle Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Tools for Bicycle Stock

When running Bicycle Therapeutics Plc price analysis, check to measure Bicycle Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bicycle Therapeutics is operating at the current time. Most of Bicycle Therapeutics' value examination focuses on studying past and present price action to predict the probability of Bicycle Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Bicycle Therapeutics' price. Additionally, you may evaluate how the addition of Bicycle Therapeutics to your portfolios can decrease your overall portfolio volatility.
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go